Expert Details ‘Pervasive’ Racial/Ethnic Opioid Access Disparities in Cancer


An expert from Dana-Farber Cancer Institute discusses data from a study investigating racial inequities in opioid access among patients of cancer near the end of life.

There were “meaningful” differences in opioid access for cancer near the end of life between Black, White, and Hispanic patients, according to Andrea C. Enzinger, MD.

CancerNetwork® spoke with Enzinger, assistant professor of medicine at Harvard Medical School and medical oncologist at Dana-Farber Cancer Institute, about data from a study investigating these disparities.

She indicated that Black patients were 4.3% less likely to receive any opioid and 3.1% less likely long-acting opioids than their White counterparts. Similar patterns were observed when Hispanic patients were compared with White patients, Enzinger said. Additionally, Black and Hispanic patients received lower average total doses of opioids compared with White patients.


We found really striking and pervasive inequities in access to prescription opioids among older, Medicare-insured patients who were dying from cancer. We looked at over 300,000 Black, White, and Hispanic patients who had a poor prognosis cancer and died between 2007 and 2019. What we saw was across a host of different measures.

If you looked at, for example, the proportion of patients who filled 1 or more opioid prescriptions in the last month of life, Black patients were about 4.3% less likely to fill any opioid prescription than White patients and Hispanic patients had a similar difference. That may sound like a small number but you have to keep in mind that by 2019, only a little over 30% of any patient filled a prescription opioid. If you’re looking at a 4.3% difference between Black and White patients with an overall cohort prevalence of about 30%, that’s a really meaningful difference.

We saw larger differences in access for long-acting opioids, which are really critical for palliating severe and persistent pain from advanced cancers. Black patients were about 3.2% less likely than White patients to fill a long-acting opioid prescription in the last month of life. And the differences are pretty similar between Hispanic and White patients. To put that in context, by 2019, only about 9% of dying patients [with cancer] filled a long-acting opioid in the last month of life; a difference of 3 or more percentage points is really huge.

We also found that when patients of color actually filled a prescription, the doses were lower. A really useful metric is to look at the difference in average total dose filled by patients of color vs White patients. As an example, Black patients received or filled about 200 morphine milligram equivalents less in the last month of life than White patients; that comes out to somewhere around 28 tablets of 5 mg oxycodone tablets in the last month of life. [That is] about 1 less pill per day for the average Black patient as compared to the average White patient. Again, we saw similar differences between Hispanic and White populations.


Enzinger AC, Ghosh K, Keating NL, et al. Racial and ethnic disparities in opioid access and urine drug screening among older patients with poor-prognosis cancer near the end of life. J Clin Oncol. Published online January 10, 2023. doi:10.1200/JCO.22.01413

Related Videos
The use of a single-port robot may allow for surgically treating more patients with head and neck cancer in a more timely manner, according to Hilary McCrary, MD, MPH.
The AACR Health Disparities Report highlights the changes needed to achieve health equity for patients with cancer.
Robert A. Winn, MD, gives insight into how institutions and community practices can improve access to cancer care.
Patients with KRAS G12C-mutated non–small cell lung cancer who have brain metastases or intolerability of intravenous infusion may be more suitable to receive a small molecule inhibitor compared with chemotherapy, says Sandip P. Patel, MD.
Treatment with sotorasib or adagrasib appears to be more tolerable among patients with KRAS G12C-mutated non–small cell lung cancer compared with docetaxel, according to Sandip Patel, MD.
Notions of blame around smoking may be a prominent factor in patients with lung cancer feeling stigmatized for developing their disease, according to Lisa Carter-Bawa PhD, MPH, APRN, ANP-C, FAAN.
Considering cystectomy in patients with bladder cancer may help with managing the shortage of Bacillus Calmette-Guerin, according to Joshua J. Meeks, MD, PhD, BS.
Anemia in patients who receive talazoparib plus enzalutamide for metastatic castration-resistant prostate cancer appears to be manageable without any compromises in patient-reported outcomes and quality of life.
Patients with locally advanced or metastatic urothelial cancer and visceral disease may particularly benefit from enfortumab vedotin plus pembrolizumab, according to Amanda Nizam, MD.
High-grade adverse effects with zanidatamab plus palbociclib and fulvestrant seem to be uncommon in patients with HER2-positive, hormone receptor–positive, metastatic breast cancer, according to Sara Hurvitz, MD, FACP.